Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés

Nepafenac

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflamma.

Prescription medicine Ophthalmic Safety alerts on record

How to use Nepafenac

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).

Cómo tomarlo y con qué frecuencia
  • One drop of ILEVRO ® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period
  • An additional drop should be administered 30 to 120 minutes prior to surgery
  • Recommended Dosing One drop of ILEVRO ® 0.3% should be applied to the affected eye one time daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period
  • An additional drop should be administered 30 to 120 minutes prior to surgery
  • Use with Other Topical Ophthalmic Medications ILEVRO ® 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics
  • If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart
Fortalezas en las que viene

Sterile ophthalmic suspension 0.3%: 1.7 mL in a 4 mL bottle and 3 mL in a 4 mL bottle. Sterile ophthalmic suspension 0.3%: 3 mL in a 4 mL bottle. ( 3 )

Infancia

The safety and effectiveness of ILEVRO ® 0.3% in pediatric patients below the age of 10 years have not been established.

Older adults

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

While you are taking it
  • Slow or Delayed Healing Inform the patient of the possibility that slow or delayed healing may occur while using NSAIDs [see Warnings and Precautions ]
  • Avoiding Contamination of the Product Instruct the patient to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections
  • Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions
  • Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery. …
Talk to a doctor first if
  • ILEVRO ® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS)
Warnings

Increased bleeding time due to interference with thrombocyte aggregation ( 5.1 ) Delayed healing ( 5.2 ) Corneal effects including keratitis ( 5.3 ) 5.1 Increased Bleeding Time With some NSAIDs including ILEVRO ® 0.3%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. It is recommended that ILEVRO ® 0.3% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. …

Posibles efectos secundarios

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 1-833-4HARROW or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …

Pregnancy and breastfeeding

8.1 Pregnancy Teratogenic Effects. Pregnancy Category C: Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. …

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-04-01.

Marcas en todo el mundo

Products with Nepafenac as the active ingredient. Names differ between countries.

Registered products

United States (FDA)

NevanacNEPAFENAC 1 mg/mL · Suspension/ Drops · Harrow Eye, LLC
NDC 82667-500Label
IlevroNEPAFENAC 3 mg/mL · Suspension/ Drops · Harrow Eye, LLC
NDC 82667-400Label
Nepafenac SterileNEPAFENAC 75 kg/75kg · Powder · Medichem S.A.
NDC 53296-0118Label
Nepafenac (non-sterile)NEPAFENAC 1.375 kg/1.375kg · Powder · Enaltec Labs Private Limited
NDC 42413-0014Label
Nepafenac (sterile)NEPAFENAC .375 kg/.375kg · Powder · Enaltec Labs Private Limited
NDC 42413-0092Label

Nigeria (NAFDAC)

NAFDACNepafenac Ophthalmic Suspension B4-5603NAFDACNevanac Eye Drop B4-3535NAFDACTevanac Ophthalmic Solution B4-9607

Other countries: check your pack's registration number and we point you to your regulator.

Safety alerts and recalls

Ilevro (nepafenac ophthalmic suspension) 0.3% 3 mL Sterile Rx Only NDC 0065-1750-14 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth, Texas 76134U.S. FDA Class II
15 Mar 2021 · Cardinal Health Inc. · TerminatedCGMP Deviations: Intermittent exposure to temperature excursion during storage.

A recall usually affects certain batches only. Compare the lot number on your pack.

Check your pack of Nepafenac

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Fuentes oficiales: FDA de EE. UU. · EMA (UE) · NAFDAC · alertas de la OMS

Questions about Nepafenac

What is Nepafenac used for?

ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ). (From the official U.S. FDA label.)

How do I take Nepafenac?

Follow your prescription or the leaflet in your pack. The official label says: One drop of ILEVRO ® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. ( 2 ) 2.1 Recommended Dosing One drop of ILEVRO ® 0.3% should be applied to the affected …

Do I need a prescription for Nepafenac?

Usually yes. Nepafenac is a prescription medicine in most countries. Rules differ by country.

What brands contain Nepafenac?

Nepafenac is sold under names such as Ilevro, Nevanac. Brand names differ between countries.

How can I check that my Nepafenac is genuine?

Scan the registration number on your pack with PillVera (NAFDAC number in Nigeria, NDC in the United States, DIN in Canada), check the expiry date and buy only from licensed pharmacies.